Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells

BACKGROUND: Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothelin. We recently demonstrated that the combine therapy of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Cancer
Prif Awduron: Matsuzawa, Fumihiko, Kamachi, Hirofumi, Mizukami, Tatsuzo, Einama, Takahiro, Kawamata, Futoshi, Fujii, Yuki, Fukai, Moto, Kobayashi, Nozomi, Hatanaka, Yutaka, Taketomi, Akinobu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2021
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7912898/
https://ncbi.nlm.nih.gov/pubmed/33637083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07722-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg